You are here

abrocitinib

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

Endpoints

clinical trials

Flag link:

Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day

Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day

BioSpace

clinical trials

atopic dermatitis

pneumococcal disease

Flag link:

Upcoming events – Pfizer's abrocitinib and Myovant's relugolix

Upcoming events – Pfizer's abrocitinib and Myovant's relugolix

EP Vantage

uterine fibroids

Flag link:

Pfizer posts detailed phase 3 data on its Dupixent rival

Pfizer posts detailed phase 3 data on its Dupixent rival

Fierce Biotech

clinical trials

atopic dermatitis

Flag link:

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

TheStreet.com

clinical trials

Flag link:

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

Endpoints

anti-inflammatories

Flag link: